-
公开(公告)号：US20240282407A1
公开(公告)日：2024-08-22
申请号：US18646644
申请日：2024-04-25
Applicant: Myriad Genetics, Inc.
Inventor： Dmitry Pruss , Brian Morris , Karla Bowles , Julie M. Eggington , Benjamin B. Roa , Alexander Gutin , Elisha Hughes
Abstract: A computer-implemented method is discussed that includes identifying, by a computer server system, stored electronic data that represents genetic sequencing for one or more genes for individuals in a population of patients who have submitted to genetic sequencing; generating, for each of multiple individuals and from the stored electronic data, probability data for the individuals and probability or weighting data, or both, for relatives of the individuals, the probability data representing likelihoods that a particular person corresponding to the probability data carries a deleterious mutation in a particular gene; and generating a score for a genetic variant, wherein the score is a function of probability or weighting data, or both, for the individuals and for relatives of the individuals, and the score represent a composite probability that a certain variant is a deleterious or benign variant.
-
公开(公告)号：US20240182979A1
公开(公告)日：2024-06-06
申请号：US18442036
申请日：2024-02-14
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia Reid
CPC classification number: C12Q1/6886 , G16B20/00 , G16B20/10 , G16B20/20 , G16B40/30 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G16B40/00
Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
-
3.发明公开公开(公告)号：US20230212653A1
公开(公告)日：2023-07-06
申请号：US18076279
申请日：2022-12-06
Applicant: Myriad Genetics, Inc.
Inventor： Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6827 , A61K33/243 , C12Q1/6886 , G16B20/20
CPC classification number: C12Q1/6827 , A61K33/243 , C12Q1/6886 , G16B20/20 , C12Q2600/154 , C12Q2600/156
Abstract: Provided herein are methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US11225685B2
公开(公告)日：2022-01-18
申请号：US16815963
申请日：2020-03-11
Applicant: MYRIAD GENETICS, INC.
Inventor： Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/6827 , G16B30/00 , C12Q1/6858 , C12Q1/6874 , C12Q1/6883
Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
-
公开(公告)号：US20210310079A1
公开(公告)日：2021-10-07
申请号：US17353279
申请日：2021-06-21
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Kirsten Timms , Alexander Gutin
IPC: C12Q1/6886 , C12Q1/6827 , C12Q1/6858 , A61K33/243 , G16B20/20
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
Patent Agency Ranking
公开(公告)号：US20170247768A1
公开(公告)日：2017-08-31
申请号：US15588458
申请日：2017-05-05
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia Reid
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G06F19/18 , G06F19/24
Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
-
公开(公告)号：US20170137890A1
公开(公告)日：2017-05-18
申请号：US15331076
申请日：2016-10-21
Applicant: Myriad Genetics, Inc.
Inventor： Jerry Lanchbury , Alexander Gutin , Darl Flake
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N2800/52 , G01N2800/54 , G16B20/00 , G16B25/00 , G16B40/00
Abstract: The disclosure provides for molecular classification of disease and, particularly, molecular markers for breast cancer prognosis and methods and systems of use thereof.
-
公开(公告)号：US20170096712A1
公开(公告)日：2017-04-06
申请号：US15237401
申请日：2016-08-15
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia Reid
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G16B25/00
Abstract: Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.
-
公开(公告)号：US20170022569A1
公开(公告)日：2017-01-26
申请号：US15192497
申请日：2016-06-24
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/68 , A61K31/282 , A61K33/24
CPC classification number: C12Q1/6886 , A61K31/282 , A61K33/24 , C12Q2600/106 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在杂合性（LOH）特征丧失的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含LOH标记的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。
-
公开(公告)号：US20160160294A1
公开(公告)日：2016-06-09
申请号：US14962588
申请日：2015-12-08
Applicant: Tesaro , Myriad Genetics, Inc.
Inventor： Keith Wilcoxen , Alexander Gutin , Kirsten Timms , Victor Abkevich , Yan Wang , Jerry Lanchbury
IPC: C12Q1/68 , A61K31/454
CPC classification number: C12Q1/6886 , A61K31/454 , C12Q2600/106 , C12Q2600/158
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.
Abstract translation: 本文件提供了评估样品（例如癌细胞）是否存在同源重组缺陷（HRD）或HRD特征以预测对尼拉帕布反应的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否含有HRD特征以预测对尼拉帕布的反应的方法和材料。
-
-
-
-
-
-
-
-
-
Search Results
68
records
(took 0.039 seconds)
